Nektar Therapeutics (NKTR)
1.255
-0.06
(-4.92%)
USD |
NASDAQ |
Apr 19, 16:00
1.27
+0.02
(+1.20%)
After-Hours: 20:00
Nektar Therapeutics Revenue (Quarterly): 23.88M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 23.88M |
| September 30, 2023 | 24.14M |
| June 30, 2023 | 20.50M |
| March 31, 2023 | 21.59M |
| December 31, 2022 | 22.02M |
| September 30, 2022 | 23.62M |
| June 30, 2022 | 21.58M |
| March 31, 2022 | 24.82M |
| December 31, 2021 | 25.01M |
| September 30, 2021 | 24.92M |
| June 30, 2021 | 28.33M |
| March 31, 2021 | 23.65M |
| December 31, 2020 | 23.46M |
| September 30, 2020 | 30.03M |
| June 30, 2020 | 48.85M |
| March 31, 2020 | 50.57M |
| December 31, 2019 | 33.86M |
| September 30, 2019 | 29.22M |
| June 30, 2019 | 23.32M |
| March 31, 2019 | 28.22M |
| December 31, 2018 | 39.83M |
| September 30, 2018 | 27.76M |
| June 30, 2018 | 1.088B |
| March 31, 2018 | 38.02M |
| December 31, 2017 | 95.47M |
| Date | Value |
|---|---|
| September 30, 2017 | 152.93M |
| June 30, 2017 | 34.59M |
| March 31, 2017 | 24.73M |
| December 31, 2016 | 37.45M |
| September 30, 2016 | 36.34M |
| June 30, 2016 | 32.77M |
| March 31, 2016 | 58.88M |
| December 31, 2015 | 39.37M |
| September 30, 2015 | 59.95M |
| June 30, 2015 | 22.66M |
| March 31, 2015 | 108.80M |
| December 31, 2014 | 19.55M |
| September 30, 2014 | 132.87M |
| June 30, 2014 | 28.51M |
| March 31, 2014 | 19.77M |
| December 31, 2013 | 31.15M |
| September 30, 2013 | 60.91M |
| June 30, 2013 | 33.86M |
| March 31, 2013 | 23.00M |
| December 31, 2012 | 21.15M |
| September 30, 2012 | 18.41M |
| June 30, 2012 | 23.68M |
| March 31, 2012 | 17.95M |
| December 31, 2011 | 15.78M |
| September 30, 2011 | 27.07M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
20.50M
Minimum
Jun 2023
50.57M
Maximum
Mar 2020
27.55M
Average
24.14M
Median
Sep 2023
Revenue (Quarterly) Benchmarks
| Stereotaxis Inc | 4.565M |
| Vanda Pharmaceuticals Inc | 45.27M |
| Cara Therapeutics Inc | 3.004M |
| Marinus Pharmaceuticals Inc | 7.19M |
| DiaMedica Therapeutics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -42.08M |
| Total Expenses (Quarterly) | 54.54M |
| EPS Diluted (Quarterly) | -0.22 |
| Enterprise Value | -61.24M |
| Gross Profit Margin (Quarterly) | 69.51% |
| Profit Margin (Quarterly) | -176.2% |
| Earnings Yield | -116.3% |
| Normalized Earnings Yield | -62.25 |